Modal Content

AbbVie Partnering Day: Immunology

AbbVie’s scientific experience with biologics serves as a strong foundation for continuing research in immunology. Beyond the disease states listed below, AbbVie is also investigating a number of additional diseases, including spondyloarthropathies, hidradenitis suppurativa, and uveitis, all of which are in late-stage development. Our early discovery programs are focused on the investigation of both targeted oral therapies and biologics. AbbVie scientists are innovators in the antibody therapeutic field, with the creation and development of proprietary Dual-Variable Domain immunoglobulins (DVD-Ig), which allows for creating combination antibodies to simultaneously target multiple pathways responsible for disease progression. Partnering Day specific areas of interest:

  • Rheumatoid Arthritis
  • GI
  • Psoriasis
  • Celiac Disease
  • Osteoarthritis
  • Lupus